格列吡嗪控释片治疗2型糖尿病有效性和安全性的多中心临床研究

目的 评价格列吡嗪控释片(瑞易宁)治疗2型糖尿病的有效性、安全性.方法 为多中心、开放性临床观察性研究.675例患者完成了本研究.对单纯生活方式干预(n=134)或已用非胰岛素促泌剂(n=305)治疗,但血糖控制不佳的患者,加用瑞易宁;对已用其他磺脲类或格列奈类促泌剂(n=236)治疗,但血糖控制不佳、安全性不好或生活...

Effect and safety of glipizide GITS in the therapy of type 2 diabetes: a multi-center clinical study

Objective To investigate the effect and safety of glipizide GITS in the therapy of type 2diabetes. Methods A total of 675 type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. Patients with inadequate glycemic control by life style intervention (n=134)or non-insulin secretagogues(n=305) were added glipizide GITS therapy for 12 weeks. Patients with inadequate glycemic control,poor safety or low life quality by other secretagogues(n =236)were changed to glipizide GITS therapy for 12 weeks. Results After treatment by glipizide GITS,HbA1c of these patients decreased (1.48 ±1.20) % ( P = 0. 0000 ), fasting blood glucose decreased ( 2.47 ± 1.38 ) mmol/L ( P= 0. 0000 ), postprandial blood glucose decreased (3.64 ±2.63)mmol/L(P = 0.0000).52. 21% patients obtained the target of HbA1c ＜6.5 %, 83.21% obtained the target of HbA1c＜ 7.0%. The incidence of mild and serious hypoglycemia were 4.59% and 0.15% respectively. In patients transferred from other insulin secretagogues to glipizide GITS,99% preferred glipizide GITS for its convenience and beneficial for life quality improvement. Conclusion Glipizide GITS is an evidently effective and safe oral hypoglycemic agents, and is beneficial to life quality improvement for type 2 diabetic patients. Therefore it can be used widely in clinic.